Grail announced a roughly $325 million private placement to fund commercial expansion, reimbursement efforts and working capital, alongside recent data showing its Galleri circulating tumor DNA test increased cancer detection sevenfold when added to standard screening. The financing drew participation from institutional investors and follows a strategic Samsung investment previously disclosed. Grail said the proceeds will extend cash runway into 2030 for its early‑detection business and support market deployment amid ongoing debates over clinical utility and reimbursement. The company’s parallel data and financing moves aim to solidify Galleri’s commercial footprint while addressing payor and clinician adoption challenges for multi‑cancer early detection via ctDNA.